NCT01653925Active, not recruiting
Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression
Source: ClinicalTrials.gov · Last updated 24 Nov 2025
Brief summary (registry, in English)
The purpose of this study is to determine whether marine omega-3 fatty acids and 5-alpha-reductase inhibitor are effective in the progression of prostate cancer for low-risk prostate cancer patients.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 120 (actual)
- First submitted
- 25 Jul 2012
- Start date
- 28 Oct 2010
- Primary completion date
- 31 Dec 2016
- Lead sponsor
- CHU de Quebec-Universite Laval
- Diseases
- Prostate cancer
- NCT number
- NCT01653925
What you commit to
- Study type: Interventional
- Participants enrolled: 120
- From 28 Oct 2010 to the primary completion date, 31 Dec 2016
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Current fish oil supplementation
- Current NSAID use
Who the study is looking for
- Low-risk prostatic neoplasms
- Candidate for active surveillance
- Informed consent
Age in the registry: 35 years to 75 years · Sex: Male · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hotel-Dieu of Quebec Coordinator of this site? Confirm its status | Québec | Canada | Unknown status |
| Institute of nutraceuticals and functional food of Laval University Coordinator of this site? Confirm its status | Québec | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.